The United States Food and Drug Administration (USFDA) has concluded its inspection of Jubilant HollisterStier LLC's contract manufacturing facility located in Spokane, WA, USA on 17 June 2026. According to reports from Business Standard, the inspection was successfully completed without any major regulatory concerns. Jubilant Pharmova announced the completion of the USFDA inspection at its contract manufacturing facility operated by Jubilant HollisterStier LLC in Spokane, Washington, USA, conducted on 17 June 2026. The disclosure was made to the exchanges in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The USFDA issued eight observations during the inspection process, as reported by Business Standard. Notably, none of these observations are related to sterility assurance concerns, indicating that the facility's sterility protocols were found to be satisfactory during the regulatory review. The company has committed to responding to these observations within 15 business days and remains committed to addressing them comprehensively. Jubilant HollisterStier LLC intends to respond to the inspection observations within 15 business days, demonstrating its commitment to regulatory compliance.
Jubilant HollisterStier LLC operates as a subsidiary of Jubilant Pharma Holding Inc., which itself is a subsidiary of Jubilant Pharma Limited, Singapore, as reported by Business Standard. This corporate structure places the facility under the umbrella of Jubilant Pharma, Singapore, which is a wholly owned subsidiary of Jubilant Pharmova. Jubilant Pharmova is an integrated global pharmaceutical company with three business segments, namely pharmaceuticals, contract research and development services, and proprietary novel drugs. The Spokane facility specialises in contract manufacturing for sterile injectables and ophthalmics.
Shares of Jubilant Pharmova shed 0.94% to ₹965.45 on the BSE following the inspection announcement. The market reaction reflects investor concerns about regulatory compliance despite the positive outcome of the USFDA inspection. The stock performance shows mixed signals with historical returns showing -3.61% over one month and -7.70% over six months, while longer-term performance remains positive with +32.66% gains over five years.
